Oregon Public Employees Retirement Fund grew its holdings in shares of Envista Holdings Co. (NYSE:NVST – Get Rating) by 0.8% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 47,668 shares of the company’s stock after purchasing an additional 362 shares during the quarter. Oregon Public Employees Retirement Fund’s holdings in Envista were worth $1,564,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also made changes to their positions in the company. Whittier Trust Co. increased its holdings in shares of Envista by 50.1% during the 2nd quarter. Whittier Trust Co. now owns 785 shares of the company’s stock worth $30,000 after buying an additional 262 shares during the last quarter. Ronald Blue Trust Inc. increased its holdings in shares of Envista by 419.3% during the 3rd quarter. Ronald Blue Trust Inc. now owns 836 shares of the company’s stock worth $32,000 after buying an additional 675 shares during the last quarter. Eagle Bay Advisors LLC acquired a new stake in shares of Envista during the 2nd quarter worth $35,000. Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in shares of Envista during the 2nd quarter worth $42,000. Finally, Covestor Ltd increased its holdings in shares of Envista by 35.0% during the 1st quarter. Covestor Ltd now owns 1,273 shares of the company’s stock worth $62,000 after buying an additional 330 shares during the last quarter.
Envista Stock Performance
Shares of NYSE NVST opened at $36.82 on Friday. The company has a quick ratio of 0.85, a current ratio of 1.09 and a debt-to-equity ratio of 0.22. The firm’s 50-day moving average price is $34.54 and its two-hundred day moving average price is $35.87. Envista Holdings Co. has a 52-week low of $31.67 and a 52-week high of $52.03. The stock has a market capitalization of $6.00 billion, a P/E ratio of 25.75, a P/E/G ratio of 1.78 and a beta of 1.40.
Analyst Upgrades and Downgrades
NVST has been the subject of a number of research analyst reports. Piper Sandler dropped their price objective on Envista from $46.00 to $44.00 and set an “overweight” rating for the company in a report on Friday, November 4th. William Blair reiterated an “outperform” rating on shares of Envista in a report on Thursday, November 3rd. Finally, Morgan Stanley lowered their price target on Envista from $49.00 to $48.00 and set an “overweight” rating for the company in a report on Thursday, October 13th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $46.17.
Envista Holdings Corporation, together with its subsidiaries, engages in the development, sale, and marketing of dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment provides dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists, and periodontists under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, and Orascoptic brands; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products under the Damon, Insignia, AOA, and Spark brands.
- Get a free copy of the StockNews.com research report on Envista (NVST)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
Receive News & Ratings for Envista Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envista and related companies with MarketBeat.com's FREE daily email newsletter.